Synthesis of oligosaccharides related to galactomannans from<i>Aspergillus fumigatus</i>and their NMR spectral data

Krylov, Vadim B.; Argunov, Dmitry A.; Solov’ev, A. S.; Petruk, M. I.; Gerbst, Alexey G.; Dmitrenok, Andrey S.; Shashkov, Alexander S.; Latgé, Jean‐Paul; Nifantiev, Nikolay E.

doi:10.1039/c7ob02734f

Cited by 36 publications

(23 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, no difference was observed between the isomeric pentasaccharides containing only ␤1,5 or alternating ␤1,5 and ␤1,6 linkages in their tetragalactofuranoside fragments. Ex-panding the catalogue of epitopes recognized can explain the occurrence of some false-positive tests obtained with enzyme immunoassays (EIAs) using EB-A2 MAb (121,122). Recently, other anti-galactofuran antibodies that seem more specific to longer ␤1,5-galactofuranose oligosaccharides have been produced (123), but the performance of these two MAbs requires clinical validation.…”

Section: Figmentioning

confidence: 99%

Aspergillus fumigatus and Aspergillosis in 2019

2019

View full text Add to dashboard Cite

SUMMARY Aspergillus fumigatus is a saprotrophic fungus; its primary habitat is the soil. In its ecological niche, the fungus has learned how to adapt and proliferate in hostile environments. This capacity has helped the fungus to resist and survive against human host defenses and, further, to be responsible for one of the most devastating lung infections in terms of morbidity and mortality. In this review, we will provide (i) a description of the biological cycle of A. fumigatus; (ii) a historical perspective of the spectrum of aspergillus disease and the current epidemiological status of these infections; (iii) an analysis of the modes of immune response against Aspergillus in immunocompetent and immunocompromised patients; (iv) an understanding of the pathways responsible for fungal virulence and their host molecular targets, with a specific focus on the cell wall; (v) the current status of the diagnosis of different clinical syndromes; and (vi) an overview of the available antifungal armamentarium and the therapeutic strategies in the clinical context. In addition, the emergence of new concepts, such as nutritional immunity and the integration and rewiring of multiple fungal metabolic activities occurring during lung invasion, has helped us to redefine the opportunistic pathogenesis of A. fumigatus.

show abstract

Section: Figmentioning

confidence: 99%

Aspergillus fumigatus and Aspergillosis in 2019

2019

View full text Add to dashboard Cite

show abstract

“…The mixture was incubated for 18 h at room temperature and then concentrated in vacuum, followed by gel-permeation chromatography on TSK HW-40(S) column (2 × 80 cm) in 0.1 M AcOH that formed the product GM-1-Biot with 75% yield. Biotinylated glycoconjugates 1–10 , GM-2 , GM-3 (see section «Epitope specificity of selected mAbs» below) used in the creation of glycoarrays on streptavidin-coated plates, were prepared similarly with 65–75% yields starting from the corresponding aminopropyl glycosides [ 27 , 28 , 31 ], synthesized using pyranoside- into -furanoside rearrangement [ 32 , 33 ].…”

Section: Methodsmentioning

confidence: 99%

Novel mouse monoclonal antibodies specifically recognize Aspergillus fumigatus galactomannan

et al. 2018

Self Cite

View full text Add to dashboard Cite

A panel of specific monoclonal antibodies (mAbs) against synthetic pentasaccharide β-D-Galf-(1→5)-[β-D-Galf-(1→5)]3-α-D-Manp, structurally related to Aspergillus fumigatus galactomannan, was generated using mice immunized with synthetic pentasaccharide-BSA conjugate and by hybridoma technology. Two selected mAbs, 7B8 and 8G4, could bind with the initial pentasaccharide with affinity constants of approximately 5.3 nM and 6.4 nM, respectively, based on surface plasmon resonance-based biosensor assay. The glycoarray, built from a series of synthetic oligosaccharide derivatives representing different galactomannan fragments, demonstrated that mAb 8G4 could effectively recognize the parental pentasaccharide while mAb 7B8 recognizes its constituting trisaccharide parts. Immunofluorescence studies showed that both 7B8 and 8G4 could stain A. fumigatus cells in culture efficiently, but not the mutant strain lacking galactomannan. In addition, confocal microscopy demonstrated that Candida albicans, Bifidobacterium longum, Lactobacillus plantarum, and numerous gram-positive and gram-negative bacteria were not labeled by mAbs 7B8 and 8G4. The generated mAbs can be considered promising for the development of a new specific enzyme-linked assay for detection of A. fumigatus, which is highly demanded for medical and environmental controls.

show abstract

“…In the course of the past few years, several synthetic strategies [ 232 , 233 , 234 ] have been developed to prepare these oligosaccharides expressed on the cell wall of various fungi, like Candida albicans and Apergillus fumigatus , as detailed in Section 14.1 and Section 14.2 .…”

Section: Fungal Infectionsmentioning

confidence: 99%

Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development

2018

View full text Add to dashboard Cite

During the last decade there has been a growing interest in glycoimmunology, a relatively new research field dealing with the specific interactions of carbohydrates with the immune system. Pathogens’ cell surfaces are covered by a thick layer of oligo- and polysaccharides that are crucial virulence factors, as they mediate receptors binding on host cells for initial adhesion and organism invasion. Since in most cases these saccharide structures are uniquely exposed on the pathogen surface, they represent attractive targets for vaccine design. Polysaccharides isolated from cell walls of microorganisms and chemically conjugated to immunogenic proteins have been used as antigens for vaccine development for a range of infectious diseases. However, several challenges are associated with carbohydrate antigens purified from natural sources, such as their difficult characterization and heterogeneous composition. Consequently, glycoconjugates with chemically well-defined structures, that are able to confer highly reproducible biological properties and a better safety profile, are at the forefront of vaccine development. Following on from our previous review on the subject, in the present account we specifically focus on the most recent advances in the synthesis and preliminary immunological evaluation of next generation glycoconjugate vaccines designed to target bacterial and fungal infections that have been reported in the literature since 2011.

show abstract

Synthesis of oligosaccharides related to galactomannans fromAspergillus fumigatusand their NMR spectral data

Cited by 36 publications

References 34 publications

Aspergillus fumigatus and Aspergillosis in 2019

Aspergillus fumigatus and Aspergillosis in 2019

Novel mouse monoclonal antibodies specifically recognize Aspergillus fumigatus galactomannan

Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development

Contact Info

Product

Resources

About